Literature DB >> 17825554

Dysferlinopathy in the Jews of the Caucasus: a frequent mutation in the dysferlin gene.

E Leshinsky-Silver1, Z Argov, L Rozenboim, S Cohen, Z Tzofi, Y Cohen, Y Wirguin, R Dabby, D Lev, M Sadeh.   

Abstract

Dysferlin encoding gene (DYS) is mutated in the autosomal recessive disorders Miyoshi myopathy, Limb Girdle Muscular Dystrophy type 2B (LGMD2B) and distal anterior compartment myopathy, causing dysferlin deficiency in muscle biopsy. Three ethnic clusters have previously been described in Dysferlinopathy: the Libyan Jewish population originating in the area of Tripoli, Italian and Spanish populations. We report another cluster of this muscular dystrophy in Israel among Jews of the Caucasus region. A genomic analysis of the dysferlin coding sequence performed in patients from this ethnic group, who demonstrated an absence of dysferlin expression in muscle biopsy, revealed a homozygous frameshift mutation of G deletion at codon 927 (2779delG) predicting a truncated protein and a complete loss of functional protein. The possible existence of a founder effect is strengthened by our finding of a 4% carrier frequency in this community. These findings are important for genetic counseling and also enable a molecular diagnosis of LGMD2B in Jews of the Caucasus region.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825554     DOI: 10.1016/j.nmd.2007.07.010

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  14 in total

Review 1.  Translational research and therapeutic perspectives in dysferlinopathies.

Authors:  Florian Barthélémy; Nicolas Wein; Martin Krahn; Nicolas Lévy; Marc Bartoli
Journal:  Mol Med       Date:  2011-05-06       Impact factor: 6.354

2.  Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia.

Authors:  Norah Alharbi; Rawan Matar; Edward Cupler; Hindi Al-Hindi; Hatem Murad; Iftteah Alhomud; Dorota Monies; Ali Alshehri; Mossaed Alyahya; Brian Meyer; Saeed Bohlega
Journal:  Front Neurosci       Date:  2022-02-22       Impact factor: 4.677

3.  Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations.

Authors:  Mafalda Cacciottolo; Gelsomina Numitone; Stefania Aurino; Imma Rosaria Caserta; Marina Fanin; Luisa Politano; Carlo Minetti; Enzo Ricci; Giulio Piluso; Corrado Angelini; Vincenzo Nigro
Journal:  Eur J Hum Genet       Date:  2011-04-27       Impact factor: 4.246

4.  Dysferlinopathy course and sportive activity: clues for possible treatment.

Authors:  C Angelini; E Peterle; A Gaiani; L Bortolussi; C Borsato
Journal:  Acta Myol       Date:  2011-10

5.  Whole Exome Sequencing Reveals DYSF, FKTN, and ISPD Mutations in Congenital Muscular Dystrophy Without Brain or Eye Involvement.

Authors:  Ozge Ceyhan-Birsoy; Beril Talim; Lindsay C Swanson; Mert Karakaya; Michelle A Graff; Alan H Beggs; Haluk Topaloglu
Journal:  J Neuromuscul Dis       Date:  2015

6.  The Clinical Outcome Study for dysferlinopathy: An international multicenter study.

Authors:  Elizabeth Harris; Catherine L Bladen; Anna Mayhew; Meredith James; Karen Bettinson; Ursula Moore; Fiona E Smith; Laura Rufibach; Avital Cnaan; Diana X Bharucha-Goebel; Andrew M Blamire; Elena Bravver; Pierre G Carlier; John W Day; Jordi Díaz-Manera; Michelle Eagle; Ulrike Grieben; Matthew Harms; Kristi J Jones; Hanns Lochmüller; Jerry R Mendell; Madoka Mori-Yoshimura; Carmen Paradas; Elena Pegoraro; Alan Pestronk; Emmanuelle Salort-Campana; Olivia Schreiber-Katz; Claudio Semplicini; Simone Spuler; Tanya Stojkovic; Volker Straub; Shin'ich Takeda; Carolina Tesi Rocha; M C Walter; Kate Bushby
Journal:  Neurol Genet       Date:  2016-08-04

7.  Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population.

Authors:  Fiona L M Norwood; Chris Harling; Patrick F Chinnery; Michelle Eagle; Kate Bushby; Volker Straub
Journal:  Brain       Date:  2009-09-18       Impact factor: 13.501

8.  Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B.

Authors:  Toshiaki Takahashi; Masashi Aoki; Naoki Suzuki; Maki Tateyama; Chikako Yaginuma; Hitomi Sato; Miho Hayasaka; Hitomi Sugawara; Mariko Ito; Emi Abe-Kondo; Naoko Shimakura; Tohru Ibi; Satoshi Kuru; Tadashi Wakayama; Gen Sobue; Naoki Fujii; Toshio Saito; Tsuyoshi Matsumura; Itaru Funakawa; Eiichiro Mukai; Toru Kawanami; Mitsuya Morita; Mineo Yamazaki; Takashi Hasegawa; Jun Shimizu; Shoji Tsuji; Shigeki Kuzuhara; Hiroyasu Tanaka; Masaru Yoshioka; Hidehiko Konno; Hiroshi Onodera; Yasuto Itoyama
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-12-15       Impact factor: 10.154

9.  Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects.

Authors:  Jens A Petersen; Thierry Kuntzer; Dirk Fischer; Maja von der Hagen; Angela Huebner; Veronika Kana; Johannes A Lobrinus; Wolfram Kress; Elisabeth J Rushing; Michael Sinnreich; Hans H Jung
Journal:  BMC Neurol       Date:  2015-10-06       Impact factor: 2.474

10.  Epidemiology of muscular dystrophies in the Mediterranean area.

Authors:  Haluk Topaloglu
Journal:  Acta Myol       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.